Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene chip technology will lead to quick and accurate genetic testing for cystic fibrosis

28.06.2004


A single genetic test that is capable of detecting all mutations involved in the development of cystic fibrosis could be just a few years away, the 20th annual conference of the European Society of Human Reproduction and Embryology heard today (Monday 28 June).

Researchers at Monash University in Melbourne, Australia, have discovered that recently developed microarray (or “gene chip”) technology* can be used successfully to detect one of the commonest cystic fibrosis (CF) genetic mutations with 100% accuracy.

This means that, once the technology has been refined, gene chips could be used to detect all CF mutations in a single, quick and easy test that would produce almost immediate results. The analysis could be carried out on embryos during preimplantation genetic diagnosis (PGD), so that only healthy embryos would be transferred to the woman. The technology could be used during PGD for other genetic diseases too.



Ms Chelsea Salvado, a PhD student working with Professor Alan Trounson and Dr David Cram at the Institute of Reproduction and Development at Monash, explained: “Currently there are many CF mutations diagnosed in the PGD laboratory, each requiring the development of a different diagnostic technique. However, the introduction of microarray technology would provide a uniform, single test, enabling PGD to be offered to couples presenting with different mutations without first having to undergo an extensive pre-clinical work-up. At present, this work-up can take anywhere between a week and six months to complete, depending on how easy it is to match the parental mutations with the markers used to prevent misdiagnosis.”

Until now, the possibilities of using microarray technology in PGD had been largely unexplored. Ms Salvado set out to discover the diagnostic potential of gene chips by testing them on the ∆F508 mutation, which is the commonest CF mutation, accounting for 80% of all CF mutations worldwide.

She created gene chips that held information on the normal and diseased versions of ∆F508 and then tested them on DNA samples obtained from single cells and from groups of ten cells. Despite some initial problems with amplifying the samples successfully, meaning that an extra step had to be added to the process, the final results showed that the gene chips could diagnose the ∆F508 mutation with 100% accuracy in the 30 samples investigated.

“This proved the concept that the ∆F508 mutation can be reliably and accurately diagnosed at the single cell level using microarray technology,” said Ms Salvado. “Further research is needed to improve the method, although many of the problems associated with the amplification of single cells would be reduced or eliminated if blastocyst biopsy (biopsy of 10 cells) was the method of choice in PGD.”

There are over 1,000 mutations known to cause CF and their frequency varies between countries and communities. “For example, in Australia 10 mutations are diagnosed routinely, all of which involve a mutation at a single point on the cystic fibrosis gene. Current work within our laboratory has shown that these point mutations may be detected with as much reliability and accuracy as the ?F508 mutation,” said Ms Salvado.

It will be at least two to three years before this discovery starts to benefit patients. She said: “This research needs to be enhanced by commercial microarray companies who have the capacity and the resources to develop more complex arrays with many different CF mutations. Further development of the method is critical to ensuring reliable microarray-based genetic diagnosis.”

However, Ms Salvado believes that her research will have a significant impact in the future on couples carrying CF mutations. “Microarray technology will lead to semi-automated genetic testing for both PGD and prenatal diagnosis, providing a rapid diagnosis, thus reducing the stress of couples waiting for a result. The introduction of microarray technology could lead to PGD being offered for all genetic diseases in the future.”

Emma Mason | alfa
Further information:
http://www.eshre.com

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>